Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.